[go: up one dir, main page]

CO2017003263A2 - Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer - Google Patents

Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer

Info

Publication number
CO2017003263A2
CO2017003263A2 CONC2017/0003263A CO2017003263A CO2017003263A2 CO 2017003263 A2 CO2017003263 A2 CO 2017003263A2 CO 2017003263 A CO2017003263 A CO 2017003263A CO 2017003263 A2 CO2017003263 A2 CO 2017003263A2
Authority
CO
Colombia
Prior art keywords
anamorelin
cancer
activity
pharmaceutical composition
composition based
Prior art date
Application number
CONC2017/0003263A
Other languages
English (en)
Inventor
William Mann
John Friend
William Polvino
Suzan Allen
Ming Lu
Elizabeth Duus
Ruben Giorgino
Enrico Baroni
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017003263(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of CO2017003263A2 publication Critical patent/CO2017003263A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen métodos de tratamiento de afecciones relacionadas con el cáncer usando anamorelina. La modalidad principal se relaciona con la afección única de pacientes que la definen mediante el tratamiento de la caquexia en un paciente humano con cáncer, que comprende la administración a dicho paciente de una cantidad terapéuticamente efectiva de anamorelina durante un período terapéuticamente efectivo, y la sorprendente capacidad observada de la anamorelina de aumentar la masa corporal magra de esta población.
CONC2017/0003263A 2014-09-04 2017-04-03 Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer CO2017003263A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (1)

Publication Number Publication Date
CO2017003263A2 true CO2017003263A2 (es) 2017-07-28

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0003263A CO2017003263A2 (es) 2014-09-04 2017-04-03 Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer

Country Status (44)

Country Link
US (5) US9675600B2 (es)
EP (2) EP3188599B1 (es)
JP (3) JP6356907B2 (es)
KR (3) KR101881264B1 (es)
CN (5) CN107375285A (es)
AP (1) AP2017009772A0 (es)
AR (1) AR103118A1 (es)
AU (1) AU2015312231B2 (es)
BR (1) BR112017003552A2 (es)
CA (1) CA2959158A1 (es)
CL (1) CL2017000494A1 (es)
CO (1) CO2017003263A2 (es)
CR (1) CR20170121A (es)
CY (1) CY1122746T1 (es)
DK (1) DK3188599T3 (es)
DO (1) DOP2017000055A (es)
EA (1) EA035578B1 (es)
EC (1) ECSP17019893A (es)
ES (1) ES2761777T3 (es)
GE (1) GEP20186939B (es)
HR (1) HRP20192345T1 (es)
HU (1) HUE046894T2 (es)
IL (1) IL250692B (es)
JO (1) JO3541B1 (es)
LT (1) LT3188599T (es)
MA (1) MA40607B1 (es)
MD (1) MD4710C1 (es)
ME (1) ME03597B (es)
MX (1) MX361741B (es)
MY (1) MY187167A (es)
NI (1) NI201700024A (es)
PE (1) PE20171109A1 (es)
PH (1) PH12017500392B1 (es)
PL (1) PL3188599T3 (es)
PT (1) PT3188599T (es)
RS (1) RS59751B1 (es)
SG (1) SG11201701567UA (es)
SI (1) SI3188599T1 (es)
SV (1) SV2017005400A (es)
TN (1) TN2017000040A1 (es)
TW (1) TWI639429B (es)
UA (1) UA120765C2 (es)
UY (1) UY36286A (es)
WO (1) WO2016036598A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CN113891722A (zh) 2018-12-20 2022-01-04 爱沐疗法公司 用于漏服剂量的花生口服免疫疗法给药计划表
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
US20220323430A1 (en) 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
BR112022005457A2 (pt) * 2019-10-24 2022-06-21 Toray Industries Agente terapêutico ou profilático para caquexia
TW202327596A (zh) * 2021-09-17 2023-07-16 瑞士商赫爾辛保健公司 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
JP2007531769A (ja) 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
CN1976921B (zh) 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
CN101686966A (zh) * 2007-02-13 2010-03-31 赫尔辛医疗（美国）有限公司 使用生长激素促分泌素治疗细胞增生疾病的方法
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN104470524A (zh) 2012-05-25 2015-03-25 拉夸里亚创药株式会社 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések

Also Published As

Publication number Publication date
CY1122746T1 (el) 2021-03-12
CL2017000494A1 (es) 2017-09-15
CN109172575A (zh) 2019-01-11
UY36286A (es) 2016-02-29
ECSP17019893A (es) 2017-05-31
US10278964B2 (en) 2019-05-07
US20190175574A1 (en) 2019-06-13
JP2017526695A (ja) 2017-09-14
CR20170121A (es) 2017-07-17
ME03597B (me) 2020-07-20
IL250692B (en) 2019-05-30
EP3188599A4 (en) 2017-10-11
CN107205389A (zh) 2017-09-26
MX361741B (es) 2018-12-14
EP3590338A3 (en) 2020-03-18
BR112017003552A2 (pt) 2017-12-05
SI3188599T1 (sl) 2020-02-28
PT3188599T (pt) 2020-01-15
UA120765C2 (uk) 2020-02-10
JP2021080281A (ja) 2021-05-27
MD20170025A2 (ro) 2017-07-31
IL250692A0 (en) 2017-04-30
PL3188599T3 (pl) 2020-06-01
TWI639429B (zh) 2018-11-01
US10894041B2 (en) 2021-01-19
CA2959158A1 (en) 2016-03-10
NI201700024A (es) 2017-07-18
PH12017500392B1 (en) 2018-08-31
EP3188599A1 (en) 2017-07-12
SG11201701567UA (en) 2017-03-30
US20210093627A1 (en) 2021-04-01
US20170296526A1 (en) 2017-10-19
NZ729673A (en) 2023-09-29
AU2015312231A1 (en) 2017-03-23
WO2016036598A1 (en) 2016-03-10
PE20171109A1 (es) 2017-08-07
MA40607B1 (fr) 2019-11-29
MY187167A (en) 2021-09-07
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
CN107375285A (zh) 2017-11-24
PH12017500392A1 (en) 2017-07-17
ES2761777T3 (es) 2020-05-21
TN2017000040A1 (en) 2018-07-04
KR101881264B1 (ko) 2018-07-23
LT3188599T (lt) 2019-12-10
JO3541B1 (ar) 2020-07-05
US20240024303A1 (en) 2024-01-25
JP6923486B2 (ja) 2021-08-18
EP3188599B1 (en) 2019-10-02
MD4710B1 (ro) 2020-09-30
MX2017002825A (es) 2017-09-28
JP2018154655A (ja) 2018-10-04
SV2017005400A (es) 2017-04-20
US11723902B2 (en) 2023-08-15
TW201613587A (en) 2016-04-16
KR20180085047A (ko) 2018-07-25
US20160067236A1 (en) 2016-03-10
CN113577073A (zh) 2021-11-02
KR20170047372A (ko) 2017-05-04
KR20210035923A (ko) 2021-04-01
JP7044918B2 (ja) 2022-03-30
EP3590338A2 (en) 2020-01-08
AP2017009772A0 (en) 2017-02-28
KR102234319B1 (ko) 2021-04-01
MD4710C1 (ro) 2021-04-30
KR102307275B1 (ko) 2021-09-30
AU2015312231B2 (en) 2017-10-19
EA035578B1 (ru) 2020-07-09
US9675600B2 (en) 2017-06-13
JP6356907B2 (ja) 2018-07-11
RS59751B1 (sr) 2020-02-28
GEP20186939B (en) 2018-12-25
HRP20192345T1 (hr) 2020-03-20
DOP2017000055A (es) 2017-08-15
AR103118A1 (es) 2017-04-19
HUE046894T2 (hu) 2020-04-28
CN113577074A (zh) 2021-11-02

Similar Documents

Publication Publication Date Title
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
MX2024010140A (es) Nuevos metodos.
MX2021002322A (es) Nuevos metodos.
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2017008516A (es) Anestesico a base de tetracaina.
GT201700041A (es) Tratamientos médicos a base de anamorelina
EA201991866A1 (ru) Комбинированная терапия
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
MX377674B (es) Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada.